The U.S. Food And Drug Administration On Friday Approved Daiichi Sankyo Co Ltds Treatment For Adult Patients With A Type Of Rare, Non-Cancerous Tumor Affecting Joints And Limbs. U.S. Fda Approves Daiichi Sankyos Treatment For Rare Joint TumorThe Label For The Treatment, Turalio, Includes A Boxed Warning Flagging The Risk Of Serious And Potentially Fatal Liver Injury.The Decision Comes Months After Independent Experts On An Advisory Panel To The Fda Voted In Favor Of Turalio As A Treatment For The Debilitating Condition Called Tenosynovial Giant Cell Tumor (Tgct).
